Kolinpharma S.p.A.

BIT:KIP Stock Report

Market Cap: €15.9m

Kolinpharma Future Growth

Future criteria checks 1/6

Kolinpharma is forecast to grow revenue at 8.1% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Personal Products earnings growth8.0%
Revenue growth rate8.1%
Future return on equity11.0%
Analyst coverage

Low

Last updated25 Oct 2023

Recent future growth updates

Recent updates

Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On Capital

Jun 17
Kolinpharma (BIT:KIP) Is Looking To Continue Growing Its Returns On Capital

What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

Dec 01
What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% Undervalued

Aug 25
An Intrinsic Calculation For Kolinpharma S.p.A. (BIT:KIP) Suggests It's 46% Undervalued

We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its Debt

Jun 08
We Think Kolinpharma (BIT:KIP) Can Stay On Top Of Its Debt

Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?

May 21
Do Kolinpharma's (BIT:KIP) Earnings Warrant Your Attention?

Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?

May 03
Is There An Opportunity With Kolinpharma S.p.A.'s (BIT:KIP) 35% Undervaluation?

Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E Ratio

Apr 13
Some Shareholders Feeling Restless Over Kolinpharma S.p.A.'s (BIT:KIP) P/E Ratio

What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

Feb 20
What Does Kolinpharma S.p.A.'s (BIT:KIP) Share Price Indicate?

Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Dec 28
Is Weakness In Kolinpharma S.p.A. (BIT:KIP) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably Well

Nov 22
These 4 Measures Indicate That Kolinpharma (BIT:KIP) Is Using Debt Reasonably Well

Earnings and Revenue Growth Forecasts

BIT:KIP - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202520N/A241
12/31/202418N/A131
12/31/202316N/A131
12/31/202216013N/A
9/30/2022140N/AN/AN/A
6/30/2022130-2-1N/A
3/31/202213001N/A
12/31/202113113N/A
9/30/2021131N/AN/AN/A
6/30/202113113N/A
3/31/2021111-11N/A
12/31/2020101-2-1N/A
9/30/202091N/AN/AN/A
6/30/20209100N/A
3/31/202010101N/A
12/31/201910112N/A
9/30/2019100N/AN/AN/A
6/30/20199001N/A
3/31/201990-11N/A
12/31/201890-10N/A
9/30/201880N/AN/AN/A
6/30/201870-20N/A
3/31/201860-10N/A
12/31/201750-10N/A
12/31/201640-10N/A
12/31/20152-1N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if KIP's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if KIP's earnings are forecast to grow faster than the Italian market

High Growth Earnings: Insufficient data to determine if KIP's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: KIP's revenue (8.1% per year) is forecast to grow faster than the Italian market (-0.2% per year).

High Growth Revenue: KIP's revenue (8.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KIP's Return on Equity is forecast to be low in 3 years time (11%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/01 09:39
End of Day Share Price 2023/09/27 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kolinpharma S.p.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luigi TardellaEnVent Capital Markets Limited
Luisa PrimiIR Top Consulting S.r.l.